Aalborg Universitet



#### Burst Transspinal Magnetic Stimulation Alleviates Nociceptive Pain in Parkinson Disease-A Pilot Phase II Double-Blind, Randomized Study

Lapa, Jorge Dornellys da Silva; da Cunha, Pedro Henrique Martins; Teixeira, Manoel Jacobsen; Brito Medeiros, Vitor Macedo; Fernandes, Ana Mércia; Silva de Morais, Adriano Donizeth; Graven-Nielsen, Thomas; Cury, Rubens Gisbert; Ciampi de Andrade, Daniel Published in: Neuromodulation: Technology at the Neural Interface

DOI (link to publication from Publisher): 10.1016/j.neurom.2022.10.043

Creative Commons License CC BY-NC-ND 4.0

Publication date: 2023

**Document Version** Accepted author manuscript, peer reviewed version

Link to publication from Aalborg University

*Citation for published version (APA):* Lapa, J. D. D. S., da Cunha, P. H. M., Teixeira, M. J., Brito Medeiros, V. M., Fernandes, A. M., Silva de Morais, A. D., Graven-Nielsen, T., Cury, R. G., & Ciampi de Andrade, D. (2023). Burst Transspinal Magnetic Stimulation Alleviates Nociceptive Pain in Parkinson Disease-A Pilot Phase II Double-Blind, Randomized Study. Neuromodulation: Technology at the Neural Interface, 26(4), 840-849. https://doi.org/10.1016/j.neurom.2022.10.043

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
You may not further distribute the material or use it for any profit-making activity or commercial gain
You may freely distribute the URL identifying the publication in the public portal -

# Neuromodulation: Technology at the Neural Interface BURST TRANS-SPINAL MAGNETIC STIMULATION ALLEVIATES NOCICEPTIVE PAIN IN PARKINSON'S DISEASE - A PILOT PHASE II DOUBLE-BLIND, RANDOMIZED STUDY

--Manuscript Draft--

Manuscript Number:	NEUROM-D-22-00240
Full Title:	BURST TRANS-SPINAL MAGNETIC STIMULATION ALLEVIATES NOCICEPTIVE PAIN IN PARKINSON'S DISEASE - A PILOT PHASE II DOUBLE-BLIND, RANDOMIZED STUDY
Article Type:	Clinical Research
Keywords:	Parkinson disease, chronic pain, spinal cord, neuromodulation, trans-spinal magnetic stimulation, burst, nociceptive pain, musculoskeletal pain, spinal cord stimulation
Abstract:	Background and aims: Nociceptive is the most prevalent pain mechanism in Parkinson disease (PD). It negatively affects quality of life and there is currently no evidence-based treatment for its control. Burst spinal cord stimulation has been used to control neuropathic pain, and recently shown to relieve pain of nociceptive origin. Here, we hypothesize that burst trans-spinal magnetic stimulation (bTsMS) reduce nociceptive pain in PD. Materials and Methods: Twenty-six patients were included in a double-blind, sham-controlled, randomized parallel trial design, and the analgesic effect of lower-cervical bTsMS was assessed in patients with nociceptive pain in PD (NCT04546529). Five-daily induction sessions were followed by maintenance sessions delivered twice a week for seven weeks. The primary outcome was the number of responders ( $\geq$ 50% reduction of average pain intensity assessed on a numerical rating scale ranging from 0-10) during the 8 weeks of treatment. Mood, quality of life, global impression of change, and adverse events were assessed throughout the study. Results: Twenty-six patients (46.2% women) were included in the study. The number of responders during treatment was significantly higher after active compared to sham bTsMS (p=0.004), mainly due to the effect of the first week of treatment, when eight (61.5%) patients responded to active and two (15.4%) responded to sham bTsMS (p=0.006); number needed to treat=2.2 at week 1. Depression symptom scores were lower after active (4.0 $\pm$ 3.1) compared to sham bTsMS (70.0%) compared to sham bTsMS (18.2%; p=0.030). Minor adverse events were reported in both arms throughout treatment sessions. One major side effect unrelated to treatment occurred in the active arm (death due to pulmonary embolism). Blinding was effective. Conclusion: bTsMS provided significant pain relief and improved the global impression of change in PD.

1	1	BURST TRANS-SPINAL MAGNETIC STIMULATION ALLEVIATES
1 2 3	2	NOCICEPTIVE PAIN IN PARKINSON'S DISEASE - A PILOT PHASE II
4 5	3	DOUBLE-BLIND, RANDOMIZED STUDY
6 7 8	4	RUNNING HEAD: Burst-TsMS for Parkinson Pain
9 10 11	5	
12 13	6	Jorge Dornellys da Silva Lapa, MD <sup>a</sup> ; Pedro Henrique Martins da Cunha, MD <sup>a</sup> ; Manoel
14 15	7	Jacobsen Teixeira, MD, PhD <sup>a</sup> , Vitor Macedo Brito Medeiros <sup>a</sup> ; Ana Mércia Fernandes,
16 17 18	8	MSc <sup>a</sup> ; Adriano Donizeth Silva de Morais, MD <sup>a</sup> ; Thomas Graven-Nielsen, PhD <sup>c</sup> ; Rubens
19 20	9	Gisbert Cury, MD, PhD <sup>a,b</sup> ; Daniel Ciampi de Andrade, MD, PhD <sup>a,c</sup> .
21 22	10	
23 24 25	11	<sup>a</sup> LIM-62, Pain Center, Department of Neurology, University of São Paulo, São Paulo,
26 27 28	12	Brazil
29 30	13	<sup>b</sup> Movement Disorders Center, Department of Neurology, School of Medicine, University
31 32	14	of São Paulo, São Paulo, Brazil
33 34 35	15	<sup>c</sup> Center for Neuroplasticity and Pain (CNAP), Department of Health Science and
36 37	16	Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark
38 39 40	17	
41 42	18	Funding
43 44	19	This study was funded by the Pain Center, HC-FMUSP, CNPq (scientific production
45 46 47	20	scholarship MJT, DCA). The Center for Neuroplasticity and Pain (CNAP) is supported
48 49	21	by the Danish National Research Foundation (DNRF121). DCA is supported by a Novo
50 51 52	22	Nordisk Grant NNF21OC0072828.
53 54	23	
55 56 57	24	
57 58 59	25	
60 61		
62 63 64		1
65		

# 26 Authorship Statement:

Daniel Ciampi de Andrade and Jorge Dornellys da Silva Lapa conceived and designed the study. Jorge Dornellys da Silva Lapa, Pedro Henrique Martins da Cunha, Vitor Macedo Brito Medeiros, and Adriano Donizeth Silva de Morais conducted patient examinations and collected clinical data. Jorge Dornellys da Silva Lapa, Daniel Ciampi de Andrade, Pedro Henrique Martins da Cunha, Vitor Macedo Brito Medeiros, and Ana Mércia Fernandes provided intellectual input in analyzing the data and performed statistical analyses. Jorge Dornellys da Silva Lapa and Daniel Ciampi de Andrade drafted the manuscript. Thomas Graven-Nielsen, Manoel Jacobsen Teixeira, and Rubens Gisbert Cury revised the manuscript for critically important intellectual content.

#### **Conflicts of interest**

38 No conflict of interest to be reported.

#### **Corresponding author:**

- 41 Associate Professor Daniel Ciampi de Andrade, MD, PhD
- 42 Address: Center for Neuroplasticity and Pain (CNAP)
- 43 Dept. of Health Science and Technology, Faculty of Medicine, Aalborg University
- 44 Fredrik Bajers Vej 7D-3, 9220 Aalborg E, Denmark.
- 45 E-mail address: dca@hst.aau.dk

#### 48 ABSTRACT

Background and aims: Nociceptive is the most prevalent pain mechanism in Parkinson disease (PD). It negatively affects quality of life and there is currently no evidence-based treatment for its control. Burst spinal cord stimulation has been used to control neuropathic pain, and recently shown to relieve pain of nociceptive origin. Here, we hypothesize that burst trans-spinal magnetic stimulation (bTsMS) reduce nociceptive pain in PD.

Materials and Methods: Twenty-six patients were included in a double-blind, shamcontrolled, randomized parallel trial design, and the analgesic effect of lower-cervical bTsMS was assessed in patients with nociceptive pain in PD (NCT04546529). Five-daily induction sessions were followed by maintenance sessions delivered twice a week for seven weeks. The primary outcome was the number of responders ( $\geq$  50% reduction of average pain intensity assessed on a numerical rating scale ranging from 0-10) during the 8 weeks of treatment. Mood, quality of life, global impression of change, and adverse events were assessed throughout the study.

Results: Twenty-six patients (46.2% women) were included in the study. The number of responders during treatment was significantly higher after active compared to sham bTsMS (p = 0.044), mainly due to the effect of the first week of treatment, when eight (61.5%) patients responded to active and two (15.4%) responded to sham bTsMS (p=0.006); number needed to treat=2.2 at week 1. Depression symptom scores were lower after active (4.0±3.1) compared to sham bTsMS (8.7±5.3; p=0.011). Patient's global impressions of change were improved after active bTsMS (70.0%) compared to sham bTsMS (18.2%; p=0.030). Minor adverse events were reported in both arms throughout treatment sessions. One major side effect unrelated to treatment occurred in the active arm (death due to pulmonary embolism). Blinding was effective.

73 Conclusion: bTsMS provided significant pain relief and improved the global impression
74 of change in PD in this phase-II trial.

Keywords: Parkinson disease, chronic pain, spinal cord, neuromodulation, trans-spinal
magnetic stimulation, burst, nociceptive pain, musculoskeletal pain, spinal cord
stimulation

#### **1. INTRODUCTION**

99 Despite having been reported since the original description of Parkinson disease (PD), 100 non-motor symptoms (NMS) remained underexplored for a long period(1). Recently, 101 there has been a steady increase in the interest on NMS since they are currently known to 102 substantially impact functioning and quality of life in PD(2). Of the several NMS, pain is 103 often reported by PD patients at all stages of disease. Pain has a large and important 104 negative impact on quality of life even in early-stage disease(3)(4)(5)(6).

PD is a multisystemic disease and its associated pathological findings can be identified in extranigral regions including non-dopaminergic systems(7)(8)(9). Indeed, some NMS are dopamine-responsive, while others are not. Dopamine-replacement therapy may not alleviate all NMS and specific treatments may be necessary to improve quality of life of patients experiencing NMS(10)(11). Dopaminergic treatment improves pain in only some PD patients, and there is no correlation between motor improvement and pain relief after dopaminergic or neuromodulatory treatments(11)(12). Pain in PD is often underassessed, and nearly half of patients do not receive medications or physical therapy. This is partially due to the lack of assessment tools validated to classify pain in PD as well as due to limited evidence-based treatment options. Current recommendations do not distinguish among different pain types in PD and they acknowledge the paucity of treatment options supported by evidence(10).

117 Chronic pain (pain lasting for more than three months and present most of the days) 118 affects 18% of the general population(13)(14). Chronic pain is present in 20% of PD 119 patients in the early stages of the disease but up to 80% of patients in later 120 stages(3)(15)(16). PD pain is divided into pain unrelated to PD and pain related to PD. 121 The later refers to chronic pain aggravated by PD or de novo pain appearing during 122 disease installation, while PD-unrelated pain refers to previous chronic pain that is not

influenced by PD(17). PD-related pain is further classified according to the International Association for the Study of Pain mechanistic classification and subsequent validation studies into nociceptive, neuropathic, and nociplastic pains syndromes(18). PD-nociceptive pain is the most frequent pain type and is present in 55% of the patients. It is more commonly located in the trunk and the lower back regions and is often localized or regional(17). It is associated with levodopa-induced dyskinesia, thus clustering away from neuropathic and nociplastic pain types in PD(17).

Spinal cord stimulation is a long-known treatment option for neuropathic pain. It was initially believed its effects stemmed from dorsal column-mediated effects and pain gate-control mechanisms(19), while it was later shown to have a much wider effect in spinal cord information processing, affecting extra-lemniscal tracts, including structures located in the anterior portions of the spinal cord(20). Lately, new evidence has shown that burst spinal cord stimulation can lead to lower back and axially located pain relief possibly due to its enhanced effects on wide dynamic range (WDR) cells. A preferential influence on medial nociceptive pathways leading to modulation of the affective dimension of pain has also been put forward(21)(22). Indeed, pain relief was shown to be higher in surgically-implanted burst stimulation compared to conventional continuous unpatterned stimulation in well-designed studies(23). This led us to conduct a pilot double-blind parallel trial to test the safety and potential analysic effects of burst trans-spinal magnetic stimulation (bTsMS) in PD-related nociceptive pain. We hypothesized that the benefits of spinal cord stimulation obtained in non-neuropathic or mixed pain syndromes could be reproduced by non-invasive stimulation to the same spinal segments by an induced electric current delivered by TsMS.

#### **2. METHODS**

# **2.1 Patients**

Our Institution's Ethics Review Board approved this study (#36024620.8.0000.0068), which was registered on clinicaltrials.gov (NCT04546529). PD patients with chronic nociceptive pain related to the disease were recruited from outpatient movement disorders clinics geographically near the outpatient pain clinics of the Hospital das Clínicas, University of São Paulo, between July 2020 and May 2021(13). Idiopathic PD was diagnosed based on the 2015 Movement Disorder Society (MDS) clinical diagnostic criteria(24). Nociceptive pain was diagnosed according to the Parkinson disease pain classification system (PD-PCS) by two independent researchers and reviewed by an expert(17). All patients provided informed consent to participate in the study.

The inclusion criteria were adults (18-85 years) with PD-related nociceptive pain persisting for more than 3 months and present most of the days. The average pain intensity (24h) score had to be  $\geq 4/10$  on a numerical rating scale (NRS). Exclusion criteria were pregnancy, breast feeding women, presence of defined chronic neuropathic pain according to the IASP grading system for neuropathic pain and a positive DN-4 (Douleur Neuropathique-4 questionnaire), previous diagnosis of dementia, known major psychiatric disorders (as assessed by the DSM-V), history of substance abuse, or work litigation issues(17)(25)(26). Demographic and clinical information about the patient was collected at the inclusion visit including physical examination to confirm PD and the presence of nociceptive pain.

# 174 2.2 Experimental design

This was an exploratory randomized, double-blind, sham-controlled, and pilot parallel trial to investigate the analgesic effects of active versus sham bTsMS in nociceptive PD-related chronic pain.

Participants were allocated into groups that either received burst trans-spinal magnetic stimulation (bTsMS) in a prolonged continuous theta burst stimulation or sham stimulation over the seventh cervical vertebra (C7) in the midline. They were randomly assigned to groups in a 1:1 ratio (using https://www.random.org/sequences), and the randomization sequence was stored in a sealed opaque envelope and was only revealed to the researchers responsible for the administration of bTsMS, and who had no other role in the study and were not allowed to interact with patients except for strictly stimulation-related communications.

Patients underwent active or sham bTsMS sessions for eight weeks. In the first
week, stimulation sessions were performed daily for five consecutive days (induction
series) followed by two sessions weekly (maintenance series) for seven more weeks.
Patients were followed for four additional weeks after the last treatment session for safety
and assessed on until the 12<sup>th</sup> week from study initiation by a phone call.

# **2.3 Burst trans-spinal magnetic stimulation**

The trans-spinal resting motor threshold (tsRMT) was determined before the first session with patients positioned in an armchair, relaxed, in a sound-attenuated room using a single pulse TMS pulse (ie, edge of the circular coil) over the C7 vertebral segment with a circular-shaped coil (MCF-125 coil with static cooling, MagVenture, Farum, Denmark) connected to a MagProX100 machine (MagVenture, Farum, Denmark). Trans-spinal motor-evoked potentials (MEP) were recorded using surface electrodes (Natus,

199 Middleton, WI, USA) located on the lower abdominal muscle (3<sup>rd</sup> lower bellies of rectus 200 abdominalis muscles). The trans-spinal rest motor threshold (ts-RMT was defined as the 201 lowest intensity eliciting a detectable motor-evoked potential in 5 out 10 trials. The 202 stimulation intensity for the bTsMS was set at the detection threshold of tsRMT.

Two different coils were used for the treatment sessions. In all instances, a circularshaped coil was positioned over the spinous process of the 7<sup>th</sup> cervical vertebra with the cable pointing to the side, with the induced electric current flowing lateral form medial in the spinal cord. A figure-of-eight (B-65) coil with active cooling (Magventure, Farum, Denmark) was placed orthogonally to circular-shaped coil. For real stimulations, the circular coil in contact with the skin was turned on, and the figure of eight coil was left off. Stimulation was delivered by three pulses at 50 Hz and repeated 400 times with an inter-stimulus interval of 200 milliseconds; 1,200 pulses were delivered per session over 1 minute and 20 seconds(27). For sham sessions, the same set up was used except that the circular coil was turned off while the figure-of-eight coil was turned on and delivered stimulation at 100% of maximal stimulator output. The figure-eight coil was placed on the circular-shaped coil to ensure proper double-blinded conditions. The figure-of-eight coil is supposed to provide the noise and vibration related to the stimulation, but would have no specific biological effect on the spinal cord since its several centimeters away from the skin. The coils were fixed by a mechanical arm, and the position was systematically controlled during the session. Additionally, in all sessions, a transcutaneous electric stimulation system was mounted over both sides of the circular coil touching the skin at the C7 level before the start of stimulation. The two carbon rubber surface electrodes were placed 5 cm from the coil edges on each side in a longitudinal orientation (Figure 1). Biphasic square wave impulses at a frequency of 100 Hz and pulse duration of 50 µs were used during both active and sham bTsMS session (Neurodyn

Portable TENS, Ibramed). The stimulation intensity was increased until there was local paresthesia without discomfort. Stimulation was started and stopped time-locked to

bTsMS.

# 228 2.4 Pain and related assessments

A full clinical and pain assessments were performed at baseline and after and eight (last) weeks. Pain intensity and adverse events were also assessed at the first, second and fourth weeks, and one month after the last stimulation session, this time by a structured phone interview. The primary outcome of the study was the number of patients reaching significant average pain relief ( $\geq$ 50% pain intensity reduction) during the eight weeks of stimulation sessions versus baseline assessment. The average pain intensity over the past 24h was assessed by a numerical rating scale (NRS) (28) ranging from 0 (no pain) to 10 (maximal pain imaginable).

# **2.5 Secondary outcomes**

Pain intensity and its frequency and severity were assessed by the composite score from PD-PCS(17). This score ranges from 0 (no pain) to 90 (maximal pain intensity, impact in activities and high frequency). Mood was assessed by the hospital anxiety and depression scale(29). Quality of life was assessed by EuroQol-5(30). Parkinson's disease motor symptoms were assessed by UPDRS part III(31). Pain interference in daily living was measured by the seven items from the short form of the brief pain inventory ranging from 0 (does not interfere) to 10 (maximal interference)(32). The global impression of change is a seven-point Likert scale that ranges the amount of improvement or aggravation after

250 improvement after treatment against all the other options(33).

## **2.6** Adverse events report

The incidence of treatment-emergent adverse events and the safety of bTsMS were assessed by measuring the number of participants who experienced serious events. Adverse events assessment was performed after each treatment session by using a dedicated questionnaire(34). Patients were asked to report any potential side-effects related to the treatment such as headaches, dizziness, nausea, blurred vision, sleepiness, paresthesia, and local pain.

# **2.7 Blinding assessment**

Care was taken not to set patients' appointments simultaneously so that waiting-room conversations were avoided and ensuring the integrity of blinding. The blinding assessment was performed at the end of the study (i.e., after eight weeks of treatment) as previously reported(34)(35), and included the following questions: i. could you tell which treatmet you received?"; ii. "If so, which was it?", iii. "If you were given the option to do so, would you choose to maintain the treatment for a longer period of time?".

# 268 2.8 Statistical analyses

The normality was verified by asymmetry and kurtosis values in addition to graphical methods(36). Categorical data were described using absolute and relative frequencies and compared through Fisher's exact test, and numerical data were described through median and quartiles and compared through Mann-Whitney's U test.

Longitudinal continuous data were analyzed through two-way repeated measures analysis of variance (ANOVA). For binary endpoints, generalized estimating equations were employed, as this approach allows considering participants with missing data on specific time points and therefore uses all available data without biasing the results under random dropouts(37)(38), so that data imputation strategies were not required. Treatment effects were estimated through group versus time interactions. All tests were two-tailed, and final p-values less than 0.05 were considered significant. All analyses were conducted using the Statistical Package for Social Sciences software (IBM SPSS Statistics for Windows, version 24.0. Armonk, NY: IBM Corp.). Since there are no other studies in the literature reporting non-invasive spinal cord stimulation for pain in PD, we included a convenience sample of PD based on previous studies using TsMS for other etiologies. Based on our findings we calculated the number necessary to treat, which will help future studies to properly estimate sample size.

#### **3. Results**

#### **3.1 Sample description**

Thirty patients were screened for participation, and twenty-six were randomized (Figure 289 2). Thirteen patients received active and 13 with sham bTsMS. Table 1 shows baseline 290 demographic and clinical characteristics of the 26 patients that received the allocated 291 interventions. The active bTsMS and sham bTsMS groups were similar in terms of 292 baseline characteristics.

**3.2 Pain assessment** 

Data from twenty-six PD patients were analyzed in an intention-to-treat approach. Pain intensity reduction  $\geq$  50% was higher after active bTsMS compared to sham bTsMS over the eight weeks of treatment (p=0.044) (Table 2). Pain intensity went from 6.2±1.7 and 7.0 $\pm$ 1.3 at baseline to 2.4 $\pm$ 2.2 and 3.9 $\pm$ 2.6 on the eighth week of stimulation after the active and sham bTsMS series, respectively. At the end of the first week (the induction) phase), eight (61.5%) responders to active bTsMS and two (15.4%) responders to sham **bTsMS** (p=0.006). The number needed to treat was 2.2 after the first week of treatment. Number of responders were no longer different between groups at 8 weeks and one month after the last stimulation day (P=0.120) (Table S1). We ran supplementary analyses to investigate differences in response to bTsMS being related to the location of the main pain syndrome. We dived patients according to the location of the main pain syndrome as being located above or below the spinal C7. There were no differences between predominant neck-shoulder-upper limb pain regions (i.e., above C7 spinal cord level) and thoraco-lumbar-lower limb (below C7 spinal cord segment) pain regions with number of responders after first week (p=0.710) and the last week (p=0.218) of treatment.

 **3.3 Secondary outcomes** 

311 Depression scores were lower after active bTsMS ( $4.0\pm3.1$ ) compared to sham bTsMS 312 ( $8.7\pm5.3$ ) (p = 0.011). Patient's clinical global impressions of change were more 313 frequently much/moderately improved after active bTsMS (70.0%) compared to sham 314 bTsMS (18.2%) (p=0.030) (Table S2). Other secondary outcomes are shown in Table 3. 315 There were no differences between groups concerning Parkinson motor symptoms 316 severity (UPDRS part III), anxiety symptoms (HADS-A), pain interference in daily 317 activities (BPI pain Interference on daily activities), quality of life (EQ-5D-3L total, and

health score), BPI pain intensity index, and PD-PCS score (Table S3).

**3.4. Dropouts and adverse events report** 

Four patients dropped out during the study. One left due to a lack of analgesic effects (after the 7<sup>th</sup> sham daily session) from the placebo group. In the active group, 3 patients dropped out of the study. One patient had dizziness that was aggravated after active stimulation that led to treatment interruption. One dropped out due to SARS-CoV 2 infection, and one had pulmonary embolism leading to death. Concerning adverse events that did not lead patients to drop out of study, two patients reported headache (one after 1 active stimulation session and one after 1 sham stimulation session) that did not persist until the next stimulation session, none of them needed analgesics. One had transient paresthesia after a one active stimulation session, one had dizziness after three sham stimulation sessions that did not need treatment, and one had transient blurred vision after two sham stimulation sessions. There were no other side effects such as seizures, nauseas, and drowsiness.

# **3.5 Blinding assessment**

After the end of the study, 21 patients (95.5%) said they could tell which protocol of treatment they received, 13 patients (62.0%) guessed it correct. Of these patients, eight (72.7%) were in sham group, and five (50.0%) were in active group (p = 0.36). Twenty patients (95.2%) said they would like to maintain the sessions of bTsMS for a more extended period if this option were offered to them.

340 4. DISCUSSION

The present results show that bTsMS had a significant analgesic effect in PD patients with nociceptive pain within the first week. An overall effect was found during the 8 weeks of treatment, the most significant pain relief occurring after the first week of daily stimulation, with 61.5% responders in active bTsMS and 15.4% responders in the sham bTsMS group. As secondary outcome bTsMS also showed a reduction in depressive symptoms, and there was an improvement in the patient's clinical global impressions of change after treatment.

Even though we were able to detect an analgesic effect of non-invasive spinal cord stimulation in PD for the first time, one needs to acknowledge that dopaminergic medication and treatment states can influence pain perception and impact in PD patients in very dynamic manner. For example, PD patients in the off medication state have shown reduced non-painful mechanical and thermal and mechanical pain thresholds compared to healthy volunteers (3)(12)(39). Dopaminergic replacement and turning on deep brain stimulation systems can restore pain thresholds towards normal values, mainly due to modulation of small fiber-mediated sensory inputs(39)(40). These data suggest that PD patients have an inherent pro-nociceptive state that can be modulated by medication or neuromodulatory interventions primarily prescribed to treat motor symptoms. However, one recurrent finding in the PD literature is the lack of correlation between pain improvement with treatment prescribed for motor symptom control, suggesting that

dopamine replacement therapy and deep brain stimulation may act on motor and NMS by different mechanism, or on a group level, responders do not have the same degree of improvement in these two types of symptoms (41). In fact, for deep brain stimulation, it has been recently shown that slight differences in the volume of activated tissue within the subthalamic nucleus can influence different cortical networks and potentially explain different clinical motor and NMS effects after deep brain stimulation (39)(42)(43).

The control of PD-related pain is so far limited. In a study using high-frequency transcranial magnetic stimulation, modulation of the primary motor cortex was attempted to relieve musculoskeletal pain in PD, there were significant analgesic effects with active versus sham stimulation as well as impacts on motor symptom, mood symptoms, and overall disease severity(44). One open label study showed that duloxetine may be effective at treating pain in PD, but this result was not confirmed in a later double-blind, randomized, placebo-controlled trial(45)(46). Indeed, the phase II double-blind, randomized, placebo-controlled study did not show significant improvement of severe pain in PD with prolonged-release oxycodone-naloxone, while treatment-related nausea and constipation was more common in the active group than the placebo group(28). Epidural SCS was tested in a single arm, prospective, non-randomized case series to treat predominant neuropathic pain in PD patients. The electrodes were implanted in the cervical or thoracic spine level, and pain average scores decreased 59% in the burst stimulation group with better results. Basic gait analysis revealed mild improvement in motor symptoms(47).

In the present study we chose to focus on pain of nociceptive mechanisms, mainly due to PD-related chronic musculoskeletal pain, because it is the most frequent subtype in PD patients. Treatment options for nociceptive PD pain are rare(3)(17)(42)(48), and it causes significant negative impact in quality of life(17). Spinal neuromodulation is thought to

control pain through potential segmental and supraspinal mechanisms. In the early days of spinal cord stimulation, analgesic effects were believed to be caused by stimulation of large myelinated fibers on the dorsal columns, which would lead to pain reduction according to the pain gate control theory(19). It was latter shown that spinal cord stimulation influences the processing of several neurophysiological responses in the spinal cord, including autonomic and motor processing(20). This argued for a broader spread of the effects of the spinal electric field, which would be likely related to its analgesic mechanisms. Additionally, spinal cord stimulation has significant effects in vasomotor control, being used to treat peripheral chronic artery disease(51) and as a potential adjunct treatment of orthostatic hypotension in atypical parkinsonism syndromes(52). More recently, spinal stimulation with burst waves was shown not to influence the dorsal column activity directly, but lead to a major effect on wide-dynamic range neurons in the dorsal horn besides and distinct influence in medial spinothalamo-cortical pathways; suggesting that burst spinal stimulation can engage widespread suprasegmental structures, including the emotional pathways of pain processing(21)(53). In experimental studies, the spinal stimulation-mediated analgesia was related to increased release of inhibitory neurotransmitters, decreased wide-dynamic cells activity, and activation of rostroventral medulla with descending modulation of nociception(54)(55)(56). In human studies, it has been reported that SCS inhibits the nociceptive flexor reflex (RIII), which related to treatment efficacy. Additionally, decrease in cortical excitability (somatosensory evoked potential-SEP) and a reduction in thalamic-to-cingulate connectivity were also reported(20)(57).

407 There is still little knowledge regarding the mechanisms behind TsMS effects. Studies 408 showed a reduction in corticospinal excitability (e.g., trans-spinal MEP) in healthy 409 subjects(58)(59). Experimental studies showed that rats under a spinal cord injury model

undergoing TsMS had higher growth-associated protein-43, 5-hydroxytryptamine expression than sham rats receiving TsMS with potential benefits in motor function recovery(60). MEPs reduction was also described in TsDCS studies associated with reductions in SEPs(49)(61). Others have reported TsDCS led to increased intracortical facilitation(61)(62)(63). A TsDCS study with chronic pain patients showed anodal stimulation compared to sham decreases nociceptive flexor reflex (RIII) linearly with a reduction of pain scores(50). These data suggest that both invasive (SCS) and non-invasive trans spinal stimulation strategies engage segmental, supra segmental, and neuro-humoral responses, which may be related to its potential analgesic effects. However, more studies in chronic pain patients need to be conducted to ascertain if both approaches are similarly effective. Our results speak for a more widespread analgesic effect of bTsMS delivered to C7, since pain located below and above the stimulated spinal cord segment were similarly positively affected by treatment.

Minor adverse events were reported in active and sham groups. One directly led one patient to drop out of study in the active group. The single major side effect (death due to pulmonary embolism) was not considered to be specifically associated with active treatment. Spinal cord stimulation is used in patients with chronic arterial insufficiency and atherosclerosis as a mean to improve blood flow secondary to sympathetic-mediated arterial vasodilation of arterioles and is considered to be safe in vasculopathy and in patients at risk for atherothrombosis or arterial occlusion(64). However, venous vascular side effects need to be taken with caution and actively monitored in future studies.

Blinding is a major challenge in spinal cord stimulation studies, in particular non-invasiveones. We created an original strategy as an attempt to mitigate this potential source of

bias. Two coils were used during the stimulation setup. Both coils were present during all sessions. Similar strategies were employed in studies on transcranial magnetic stimulation(27)(65). Furthermore, active cutaneous electrical stimulation was used to mitigate unblinding. The efficacy of the blinding strategy suggests participants in the active group had a similar percentage of correct guessing in which group they were allocated to as patients from the sham arm.

There are several limitations in this study that should be noted. First, due to it is exploratory nature, it was primarily designed to explore the feasibility, and temporal profile of the technique in PD patients with pain. The effects found here will be valuable in the design of future studies, but smaller studies usually tend to overestimate treatment effects, and this needs to be taken into account when interpreting the results(66). Also, while we found an overall effect of active stimulation over the first eight weeks, this effect was only significant, and was mainly driven, by the period when stimulation was delivered daily, during induction sessions (i.e., after 1 week of treatment). That means that dosing remains to be determined for bTsMS, and one cannot currently know whether our maintenance sessions were adapted to maintain the effects seen after induction, or if these effects will only exist during daily stimulations, not being amenable to be sustained for longer periods of time by sessions spaced for more than one day. This distinction is central for a potential future use of the technique in clinical practice. Another point is that patients included in the study could have pain in body segments above the stimulation level (ie, C7). We decided to proceed with such a strategy based on several facts. One is that while the pain location can be located above C7, MSK pain commonly leads to referred pain, so that pain location and lesion site quite often do not coincide spatially. Additionally, pain of nociceptive nature in PD is mainly located axially, and in more than one site (17). Based on data suggesting the rather diffuse analgesic effects of burst spinal

cord stimulation, we hypothesized that the effects would not be segmentary restricted. However, while it is generally acknowledged that spinal cord stimulation may have suprasegmental neurophysiological effects, it is not known whether analgesic effects extend above the stimulation level in non-invasive trans-spinal approaches(67)(68)(69)(70). Our analyses comparing patients with predominant pain located above C7 and those with main pain located at body parts innervated by spinal cord segments below C7 were not different. Still, due to the exploratory nature of this study and its subsequent small sample, claims that bTsMS had diffuse analgesic effects need to be tuned down before larger samples are studied. Finally, this study had no mechanistic exploration of the effects of bTsMS. Neurophysiological, neuroimaging and psychophysical changes caused by bTsMS may provide valuable insights in following studies. In conclusion, this pilot trial suggests bTsMS provided analgesia predominately within the first week of daily sessions and was safe in nociceptive pain in PD. More studies are needed to deepen knowledge about this technique as an adjunct therapy to nociceptive pain. 

# **REFERENCES**

- 484 1. Jost WH, Reichmann H. "An essay on the shaking palsy" 200 years old. J Neural
  485 Transm. 2017;124(8):899–900.
- 486 2. Antonini A, Albin RL. Dopaminergic treatment and nonmotor features of
  487 Parkinson disease: The horse lives. Neurology. 2013;80(9):784–5.
- 488 3. Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson's disease:

489 Prevalence and characteristics. Pain. 2009;141(1–2):173–7.

- 490 4. Roh JH, Kim BJ, Jang JH, Seo WK, Lee SH, Kim JH, et al. The relationship of
- 491 pain and health-related quality of life in Korean patients with Parkinson's
- 492 disease. Acta Neurol Scand. 2009;119(6):397–403.
- 493 5. Camacho-Conde JA, Campos-Arillo VM. The phenomenology of pain in
  494 Parkinson's disease. Korean J Pain. 2020;33(1):90–6.
- 495 6. Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of
  496 Parkinson's disease with deep brain stimulation. Lancet Neurol. 2012;11(5):429–
  497 42.
- 498 7. Braak H, Braak E, Yilmazer D, Schultz C, de Vos R, Jansen E. Nigral and
- 499 extranigral pathology in Parkinson's disease. J Neural Transm Suppl.
- 500 1995;(46):15–31.
- 501 8. Klingelhoefer L, Reichmann H. Parkinson's disease as a multisystem disorder. J
  502 Neural Transm. 2017;124(6):709–13.
- 5039.Rukavina K, Leta V, Sportelli C, Buhidma Y, Duty S, Malcangio M, et al. Pain504in Parkinson's disease: New concepts in pathogenesis and treatment. Curr Opin505Neurol. 2019;32(4):579–88.
- 56 506 10. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret
   57
   58 507 S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—

1	508		an evidence-based medicine review. Mov Disord. 2019;34(2):180-98.
1 2 3	509	11.	Jost WH, Buhmann C. The challenge of pain in the pharmacological management
4 5	510		of Parkinson's disease. Expert Opin Pharmacother. 2019;20(15):1847-54.
6 7 8	511	12.	Cury RG, Galhardoni R, Fonoff ET, Dos MG, Ghilardi S, Fonoff F, et al. Effects
9 10	512		of deep brain stimulation on pain and other nonmotor symptoms in Parkinson
11 12 13	513		disease. Neurology. 2014;83(16):1403-9.
14 15	514	13.	Treede R, Rief W, Barke A, Finnerup NB, Scholz J, First MB, et al. Chronic pain
16 17 10	515		as a symptom or a disease: the IASP Classification of Chronic Pain for the
10 19 20	516		International Classification of Diseases (ICD-11). Pain. 2018;160(1):19-27.
21 22	517	14.	Sá KN, Moreira L, Baptista AF, Yeng LT, Teixeira MJ, Galhardoni R, et al.
23 24 25	518		Prevalence of chronic pain in developing countries: Systematic review and meta-
26 27	519		analysis. Pain Reports. 2019;4(6):1-8.
28 29 30	520	15.	Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, et al. Pain
31 32	521		as a Nonmotor Symptom of Parkinson Disease Evidence From a Case-Control
33 34 35	522		Study. Arch Neurol. 2008;65(9):1191–4.
35 36 37	523	16.	Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, et al. Pain
38 39	524		and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry.
40 41 42	525		2006;77(7):822–5.
43 44	526	17.	Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, et al.
45 46 47	527		The Parkinson disease pain classification system: results from an international
48 49	528		mechanism-based classification approach. Pain. 2021;162(4):1201-10.
50 51 52	529	18.	Freynhagen R, Parada HA, Calderon-Ospina CA, Chen J, Rakhmawati Emril D,
53 54	530		Fernández-Villacorta FJ, et al. Current understanding of the mixed pain concept:
55 56	531		a brief narrative review. Curr Med Res Opin. 2019;35(6):1011-8.
57 58 59	532	19.	Melzack R, Wall P. Pain mechanisms: a new theory. Science (80-). 1965;
60 61			
62 63 64			22
65			

1	533	20.	De Andrade DC, Bendib B, Hattou M, Keravel Y, Nguyen JP, Lefaucheur JP.
1 2 3	534		Neurophysiological assessment of spinal cord stimulation in failed back surgery
4 5	535		syndrome. Pain. 2010 Sep;150(3):485–91.
6 7 8	536	21.	De Ridder D, Vanneste S. Burst and tonic spinal cord stimulation: Different and
9 10	537		common brain mechanisms. Neuromodulation. 2016;19(1):47-59.
11 12 13	538	22.	Chakravarthy K, Fishman MA, Zuidema X, Hunter CW, Levy R. Mechanism of
14 15	539		Action in Burst Spinal Cord Stimulation: Review and Recent Advances. Pain
16 17	540		Med (United States). 2019;20(Suppl 1):S13-22.
18 19 20	541	23.	Kirketeig T, Schultheis C, Zuidema X, Hunter CW, Deer T. Burst Spinal Cord
21 22	542		Stimulation: A Clinical Review. Pain Med (United States). 2019;20(Suppl
23 24 25	543		1):S31–40.
26 27	544	24.	Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS
28 29 30	545		clinical diagnostic criteria for Parkinson's disease. Mov Disord.
31 32	546		2015;30(12):1591–601.
33 34 35	547	25.	Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira
36 37	548		D, et al. Neuropathic pain: An updated grading system for research and clinical
38 39	549		practice. Pain. 2016;157(8):1599-606.
40 41 42	550	26.	de Andrade DC, Ferreira KASL, Nishimura CM, Yeng LT, Batista AF, de Sá K,
43 44	551		et al. Psychometric validation of the Portuguese version of the Neuropathic Pain
45 46 47	552		Symptoms Inventory. Health Qual Life Outcomes. 2011;9:107.
48 49	553	27.	De Martino E, Fernandes AM, Galhardoni R, De Oliveira Souza C, Ciampi De
50 51 52	554		Andrade D, Graven-Nielsen T. Sessions of Prolonged Continuous Theta Burst
53 54	555		Stimulation or High-frequency 10 Hz Stimulation to Left Dorsolateral Prefrontal
55 56 57	556		Cortex for 3 Days Decreased Pain Sensitivity by Modulation of the Efficacy of
57 58 59	557		Conditioned Pain Modulation. J Pain. 2019;20(12):1459-69.
60 61			
62 63 64			23
65			

1	558	28.	Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M,
1 2 3	559		et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in
4 5	560		patients with Parkinson's disease (PANDA): A double-blind, randomised,
6 7 8	561		placebo-controlled trial. Lancet Neurol. 2015;14(12):1161-70.
9 10	562	29.	Botega NJ, Bio MR, Zomignani MA, Garcia C, Pereira WA. Mood disorders
11 12 13	563		among inpatients in ambulatory and validation of the anxiety and depression
14 15	564		scale HAD. Rev Saude Publica. 1995;29(5):355-63.
16 17	565	30.	Santos M, Cintra MACT, Monteiro AL, Santos B, Gusmão-Filho F, Andrade
19 20	566		MV, et al. Brazilian valuation of EQ-5D-3L health states. Med Decis Mak.
21 22	567		2016;36(2):253–63.
23 24 25	568	31.	Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et
26 27	569		al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's
28 29 30	570		Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing
31 32	571		results. Mov Disord. 2008;23(15):2129-70.
33 34 35	572	32.	Ferreira KA, Teixeira MJ, Mendonza TR, Cleeland CS. Validation of brief pain
36 37	573		inventory to Brazilian patients with pain. Support Care Cancer. 2011;19(4):505-
38 39 40	574		11.
40 41 42	575	33.	De Lima MS, Soares BGDO, Paoliello G, Vieira RM, Martins CM, Neto JIDM,
43 44	576		et al. The Portuguese version of the Clinical Global Impression - Schizophrenia
45 46 47	577		Scale: Validation study. Rev Bras Psiquiatr. 2007;29(3):246-9.
48 49	578	34.	Rocha RDO, Teixeira MJ, Yeng LT, Cantara MG, Faria VG, Liggieri V, et al.
50 51 52	579		Thoracic sympathetic block for the treatment of complex regional pain syndrome
53 54	580		type I: A double-blind randomized controlled study. Pain. 2014;155(11):2274–
55 56 57	581		81.
57 58 59 60	582	35.	Dongyang L, Fernandes AM, da Cunha PHM, Tibes R, Sato J, Listik C, et al.
61 62 63 64 65			24

1	583		Posterior-superior insular deep transcranial magnetic stimulation alleviates
1 2 3	584		peripheral neuropathic pain — A pilot double-blind, randomized cross-over
4 5	585		study. Neurophysiol Clin. 2021;51(4):291–302.
6 7 8	586	36.	Harrell Jr F. Regression Modeling Strategies With Applications to Linear
9 10	587		Models, Logistic and Ordinal Regression, and Survival Analysis. Cham:
11 12 13	588		Springer-Verlag; 2015. 582 p.
14 15	589	37.	Fitzmaurice G, Laird N, Ware J. Applied longitudinal analysis. 2nd ed. Hoboken,
16 17	590		NJ: Wiley; 2012. 752 p.
18 19 20	591	38.	Twisk J. Applied Longitudinal Data Analysis for Epidemiology: A Practical
21 22	592		Guide. Second ed. Amsterdam: Cambridge University Press; 2013. 321 p.
23 24 25	593	39.	Ciampi De Andrade D, Lefaucheur JP, Galhardoni R, Ferreira KSL, Brandão
26 27	594		Paiva AR, Bor-Seng-Shu E, et al. Subthalamic deep brain stimulation modulates
28 29 30	595		small fiber-dependent sensory thresholds in Parkinson's disease. Pain.
31 32	596		2012;153(5):1107–13.
33 34 35	597	40.	Slaoui T, Mas-Gerdelat A, Ory-Magne F, Rascol O, Brefel-Courbon C. La
36 37	598		lévodopa modifie les seuils nociceptifs chez le patient parkinsonien. Rev Neurol
38 39	599		(Paris). 2007;163(1):66–71.
40 41 42	600	41.	Cury RG, Galhardoni R, Teixeira MJ, Dos Santos Ghilardi MG, Silva V,
43 44	601		Myczkowski ML, et al. Subthalamic deep brain stimulation modulates conscious
45 46 47	602		perception of sensory function in Parkinson's disease. Pain. 2016;157(12):2758-
48 49	603		65.
50 51 52	604	42.	Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG. The benefit of subthalamic deep
53 54	605		brain stimulation for pain in parkinson disease: A 2-year follow-up study.
55 56 57	606		Neurosurgery. 2012;70(1):18–23.
57 58 59 60	607	43.	Spielberger S, Wolf E, Kress M, Seppi K, Poewe W. The influence of deep brain
61 62 63 64			25
65			

1	608		stimulation on pain perception in Parkinson's disease. Mov Disord.
1 2 3	609		2011;26(7):1367–8.
4 5	610	44.	Li J, Mi TM, Zhu B fan, Ma JH, Han C, Li Y, et al. High-frequency repetitive
6 7 8	611		transcranial magnetic stimulation over the primary motor cortex relieves
9 10	612		musculoskeletal pain in patients with Parkinson's disease: A randomized
11 12	613		controlled trial. Park Relat Disord. 2020 Nov 1;80:113–9.
13 14 15	614	45.	Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of
16 17	615		duloxetine on primary pain symptoms in Parkinson disease. Clin
18 19 20	616		Neuropharmacol. 2007;30(4):201–5.
21 22	617	46.	Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, et al. A double-
23 24 25	618		blind, randomized controlled trial of duloxetine for pain in Parkinson's disease. J
26 27	619		Neurol Sci. 2020;414:116833.
28 29 20	620	47.	Chakravarthy K V., Chaturvedi R, Agari T, Iwamuro H, Reddy R, Matsui A.
30 31 32	621		Single arm prospective multicenter case series on the use of burst stimulation to
33 34	622		improve pain and motor symptoms in Parkinson's disease. Bioelectron Med.
35 36 37	623		2020;6(1):4–11.
38 39	624	48.	Lee MA, Walker RW, Hildreth TJ, Prentice WM. A Survey of Pain in Idiopathic
40 41 42	625		Parkinson's Disease. J Pain Symptom Manage. 2006;32(5):462-9.
43 44	626	49.	Cogiamanian F, Vergari M, Pulecchi F, Marceglia S, Priori A. Effect of spinal
45 46 47	627		transcutaneous direct current stimulation on somatosensory evoked potentials in
48 49	628		humans. Clin Neurophysiol. 2008;119(11):2636–40.
50 51	629	50.	Guidetti M, Ferrucci R, Vergari M, Aglieco G, Naci A, Versace S, et al. Effects
52 53 54	630		of Transcutaneous Spinal Direct Current Stimulation (tsDCS) in Patients With
55 56	631		Chronic Pain: A Clinical and Neurophysiological Study. Front Neurol. 2021;12.
57 58 59	632	51.	Mingyuan W, Bengt L, Robert D. F. Putative mechanisms behind effects of
60 61			
62 63 64			20
65			

1	633		spinal cord stimulation on vascular diseases. 2009;138(405):9-23.	
1 2 3	634	52.	Squair JW, Berney M, Castro Jimenez M, Hankov N, Demesmaeker R, Amir S,	
4 5	635		et al. Implanted System for Orthostatic Hypotension in Multiple-System Atrophy	y.
6 7 8	636		N Engl J Med. 2022;386(14):1339–44.	
9 10	637	53.	Tang R, Martinez M, Goodman-Keiser M, Farber JP, Qin C, Foreman RD.	
11 12	638		Comparison of burst and tonic spinal cord stimulation on spinal neural processin	g
13 14 15	639		in an animal model. Neuromodulation. 2014;17(2):143-51.	
16 17	640	54.	Linderoth B, Meyerson BA. Spinal cord stimulation: Exploration of the	
18 19 20	641		physiological basis of a widely used therapy. Anesthesiology. 2010;113(6):1265	_
21 22	642		7.	
23 24 25	643	55.	Guan Y, Wacnik PW, Yang F, Carteret AF, Chung C-Y, Meyer RA, et al. Spinal	l
26 27	644		Cord Stimulation-induced Analgesia Electrical Stimulation of Dorsal Column	
28 29 30	645		and Dorsal Roots Attenuates Dorsal Horn Neuronal Excitability in Neuropathic	
31 32	646		Rats. Anesthesiology. 2010;113(6):1392-405.	
33 34 25	647	56.	Song Z, Ansah OB, Meyerson BA, Pertovaara A, Linderoth B. The	
36 37	648		rostroventromedial medulla is engaged in the effects of spinal cord stimulation in	1
38 39	649		a rodent model of neuropathic pain. Neuroscience. 2013;247:134-44.	
40 41 42	650	57.	Moens M, Sunaert S, Mariën P, Brouns R, De Smedt A, Droogmans S, et al.	
43 44	651		Spinal cord stimulation modulates cerebral function: An fMRI study.	
45 46 47	652		Neuroradiology. 2012;54(12):1399-407.	
48 49	653	58.	Insausti-Delgado A, Lopez-Larraz E, Nishimura Y, Birbaumer N, Ziemann U,	
50 51 52	654		Ramos-Murguialday A. Quantifying the effect of trans-spinal magnetic	
53 54	655		stimulation on spinal excitability. Int IEEE/EMBS Conf Neural Eng NER.	
55 56 57	656		2019;2019-March:279–82.	
57 58 59	657	59.	Nakagawa K, Nakazawa K. Static magnetic field stimulation applied over the	
60 61				
62 63 64			2	7
65				

1	658		cervical spinal cord can decrease corticospinal excitability in finger muscle. Cli	in
1 2 3	659		Neurophysiol Pract. 2018;3:49–53.	
4 5	660	60.	Liu H, Xiong D, Pang R, Deng Q, Sun N, Zheng J, et al. Effects of repetitive	
6 7 8	661		magnetic stimulation on motor function and GAP43 and 5-HT expression in rat	ts
9 10	662		with spinal cord injury. J Int Med Res. 2020;48(12).	
11 12 13	663	61.	Lenoir C, Jankovski A, Mouraux A. Anodal Transcutaneous Spinal Direct	
14 15	664		Current Stimulation (tsDCS) Selectively Inhibits the Synaptic Efficacy of	
16 17 18	665		Nociceptive Transmission at Spinal Cord Level. Neuroscience. 2018;393:150-	
19 20	666		63.	
21 22 22	667	62.	Murray LM, Knikou M. Repeated cathodal transspinal pulse and direct current	
23 24 25	668		stimulation modulate cortical and corticospinal excitability differently in health	ıy
26 27	669		humans. Exp Brain Res. 2019;237(7):1841–52.	
28 29 30	670	63.	Murray LM, Islam MA, Knikou M. Cortical and Subcortical Contributions to	
31 32	671		Neuroplasticity after Repetitive Transspinal Stimulation in Humans. Terao Y,	
33 34 35	672		editor. Neural Plast. 2019;2019:4750768.	
36 37	673	64.	Saini HS, Shnoda M, Saini I, Sayre M, Tariq S. The Effects of Spinal Cord	
38 39 40	674		Stimulators on End Organ Perfusion: A Literature Review. Cureus.	
41 42	675		2020;12(3):e7253.	
43 44	676	65.	Galhardoni R, Da Silva VA, García-Larrea L, Dale C, Baptista AF, Barbosa LM	М,
45 46 47	677		et al. Insular and anterior cingulate cortex deep stimulation for central	
48 49	678		neuropathic pain disassembling the percept of pain. Neurology.	
50 51 52	679		2019;92(18):E2165-75.	
53 54	680	66.	Faber J, Fonseca LM. How sample size influences research outcomes. Dental	
55 56 57	681		Press J Orthod. 2014;19(4):27–9.	
58 59	682	67.	Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V	, ,
60 61				
63 64				28
65				

1	683		et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial
1 2 3	684		magnetic stimulation (rTMS): An update (2014–2018). Clin Neurophysiol.
4 5	685		2020;131(2):474–528.
6 7 8	686	68.	Al-Kaisy A, Baranidharan G, Sharon H, Palmisani S, Pang D, Will O, et al.
9 10	687		Comparison of Paresthesia Mapping With Anatomic Placement in Burst Spinal
11 12 13	688		Cord Stimulation: Long-Term Results of the Prospective, Multicenter,
14 15	689		Randomized, Double-Blind, Crossover CRISP Study. Neuromodulation.
16 17 18	690		2022;25(1):85–93.
19 20	691	69.	De Carolis G, Paroli M, Tollapi L, Doust M, Burgher AH, Yu C, et al.
21 22 23	692		Prospective Evaluation Paresthesia-Independence: An Assessment of Technical
24 25	693		Factors Related to 10 kHz Paresthesia-Free Spinal Cord Stimulation. Pain
26 27	694		Physician. 2017;20:331–41.
28 29 30	695	70.	Bannister K, Kucharczyk MW, Graven-Nielsen T, Porreca F. Introducing
31 32	696		descending control of nociception: a measure of diffuse noxious inhibitory
33 34 35	697		controls in conscious animals. Pain. 2021;162(7):1957-9.
36 37	698		
38 39 40	699		
41			
42 43			
44			
45 46			
47			
48			
49 50			
51			
52			
53			
54			
55 56			
57			
58			
59			
60			
७⊥ 62			
63			
64			
65			

1 2 3	701	
4 5	702	Figure 1. Stimulation montage.
6 7 8	703	Figure 2. CONSORT study diagram.
9 10	704	
9 0 1 1 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	704	
65		

**FIGURE LEGENDS** 

1	706	TABLES	
⊥ 2 3	707	Table 1. Demographic profile and baseline characteristics of subjects included in	the
4 5	708	study.	
6 7 8 9	709 710	Table 2. Influence of bTsMS on pain response within the first eight weeks.	
$\begin{array}{c}10\\11\\13\\14\\56\\7\\89\\01\\22\\22\\22\\22\\22\\22\\22\\22\\22\\22\\22\\22\\22$	711 712	Table 3. Secondary outcomes.	
63 64 65			31

		Sham bTsMS (n=13)	Active bTsMS (n= 13)	
Age (years) <sup>A</sup>		61.4±9.2(42-79)	61.9±10.3(36-73)	
Sex, n (%)	Male	9(69.2)	5(38,5)	
Schooling, n (%)	< 12 years	7(53.8)	5(38.5)	
	> 12 years	6(46.2)	8(61.5)	
Etiology of musculoskeletal	Myofascial pain syndrome	12(92.3)	12(92.3)	
pain, n (%)	Coat hanger headache	2(15.4)	2(15.4)	
	Localized pain	4(30.8)	3(23.1)	
Handedness, n (%)	Right-handed	12(92.3)	13(100.0)	
Time since Parkinson disease		9.3±7.5(0-26)	10.9± 5.2(1-20)	
's diagnosis (years) <sup>A</sup>				
Levodopa equivalent <sup>A</sup>		936.4±468.7(300-1905)	847.8±425.7(150-1564)	

Table 1. Demographical profile and baseline assessment characteristics of subjects included in the study.

Side of initial motor	Left	7(50.0)	7(50.0)
symptom, n (%)			
	Right	6(50.0)	6(50.0)
	Bilateral	7(53.8)	11(84.6)
Predominant pain side, n (%)	Left	3(23.1)	2(15.4)
	Right	3(23.1)	0(0.0)
Pain location, n (%)	Neck	5(38.5)	4(30.8)
	Shoulder	5(38.5)	6(46.1)
	Upper limb	2(15.4)	3(23.1)
	Upper back	1(7.7)	2(15.4)
	Low back	9(69.2)	10(76.9)
	Lower Limb	9(69.2)	9(69.2)

Table 1(continued). Demographical profile and baseline assessment characteristics of subjects included in the study.

Duration of pain (years) <sup>B</sup>		4.5±3.9(0.5-5)	5.6±5.4(1-8)
Average pain (BPI) <sup>A</sup>		7.0±1.3(5-10)	6.1±1.7(4-10)
New pain in the last		1(7.7)	3(23.1)
evaluation, n (%)			
Rehabilitation, n (%)		6(46.2)	8(61.5)
Pain catastrophizing scale <sup>A</sup>		26.4±14.5	27.0±9.0
HADS	Depression subscale	7.6±5.6	7.1±3.2
	Anxiety subscale	9.5±5.2	7.7±3.2
Motor complications in	Motor fluctuations	6(46.2)	6(46.2)
Parkinson disease, n (%)	Dyskinesia	5(38.5)	7(53.8)
	Gait problems	9(69.2)	10(61.5)
UPDRS part III		33.2±16.3(10-67)	43.0±16.1(14-66)

Table 1(continued). Demographical profile and baseline assessment characteristics of subjects included in the study.

Hoehn and Yahr scale, n (%)	Unilateral	2(15.4)	2(15.4)
	Bilateral	8(61.5)	11(84.6)
	Bilateral with balance and	3(23.1)	0(0.0)
	postural impairment		
DBS, n (%)		3(23.1)	2(15.4)

Table 1(continued). Demographical profile and baseline assessment characteristics of subjects included in the study.

<sup>A</sup> Values are presented in: mean ± SD (minimum and maximum); <sup>B</sup> Values are present in: medium (quartiles);

bTsMS: burst trans-spinal magnetic stimulation BPI: brief pain inventory; HADS: Hospital anxiety and depression scale;

UPDRS: total unified Parkinson disease rating scale; DBS: Deep brain stimulation.

Table 3. Secondary outcomes.

		(N=26)	(N=22)
	Group	Baseline	Eighth Week
PD-PCS score	Active bTsMS	43.4±20.0(12-90)	10.0±13.8(0-42)
	Sham bTsMS	43.2±22.1(12-72)	26.2±23.1(0-63)
HADS-D*	Active bTsMS	7.1±3.2(2-12)	4.0±3.1(0-9)
	Sham bTsMS	7.6±5.6(1-21)	8.7±5.3(2-18)
HADS-A	Active bTsMS	7.7±3.2(2-12)	4.1±2.3(1-8)
	Sham bTsMS	9.5±5.2(2-20)	6.6±5.1(1-16)
EQ-5D-3L total	Active bTsMS	0.44±0.13(0.30-0.74)	0.67±0.15(0.49-0.85)
	Sham bTsMS	0.49±0.14(0.17-0.69)	0.53±0.19(0.35-0.85)
EQ-5D-3L Health Score	Active bTsMS	56.4±5.23.8(0-95)	71.9±14.5(50-99)
	Sham bTsMS	55.8±29.5(1-85)	62.9±22.7(10-95)
UPDRS part III	Active bTsMS	43.0±16.1(14-66)	36.0±8.6(22-48)
	Sham bTsMS	33.2±16.3(10-67)	38.0±17.0(10-78)
BPI Pain Intensity Index	Active bTsMS	54.8±18.3.8(27.5-90.0)	19.8±19.8(0.0-55.0)
	Sham bTsMS	57.1±12.6(35.0-77.5)	35.6±21.6(0.0-75.0)
BPI Pain Interference on daily activities	Active bTsMS	65.4±17.8(31.9-90.0)	21.3±30.0(0.0-74.3)
	Sham bTsMS	68.2±18.3(42.9-97.1)	45.3±34.3(0.0-94.3)

Values are presented in: mean ± SD (minimum and maximum); bTsMS: burst trans-spinal magnetic stimulation; PD-PCS score: Parkinson Disease Pain Classification system score; HADS-D: depression subscale of the hospital anxiety and depression scale; HADS-A: anxiety subscale of the hospital anxiety and depression scale; EQ-5D-3L: the three-level EuroQol five-dimensional questionnaire; UPDRS part III: unified Parkinson's disease rating scale part III; BPI: Brief pain inventory; \* P<0.05 (results obtained by two-way repeated measures ANOVA analysis between baseline and eighth week based on group-by-time interaction effect).

	(N=26)				
	β	Standard Error	OR	95% CI	р
Intercept	-1.338	0.5924	0.261	0.082-0.834	0.023*
Week	0.111	0.0784	1.138	0.977-1.327	0.099
Active treatment group	1.347	0.6689	3.844	1.036-14.262	0.044*

Table 2. Influence of bTsMS on pain response within the first eight weeks.

Results obtained by Generalized Estimating Equations (GEE) analysis, weeks 1-8 included as a covariate;

Pain intensity [Average NRS (numerical rating scale; 0-10)]; bTsMS: burst trans-spinal magnetic stimulation.

\* P<0.05. Pain response defined as pain intensity reduction of at least 50% compared to baseline.

Figure 1

# Figure 1. Stimulation montage.



A) Surface electrodes of TENS secured to the skin with adhesive tape at level of C7 in the paraspinal area. B) The circular-shaped coil placed perpendicular to spinal in midline over C7. C) The figure-eight coil was placed orthogonally to circular-shaped coil. This last image shows complete montage during all bTsMS sessions regardless of group.

TENS: Transcutaneous electrical nerve stimulation; C7: Seventh cervical vertebrae; bTsMS: Burst trans-spinal magnetic stimulation

Figure 2. CONSORT study diagram.



bTsMS: burst trans-spinal magnetic stimulation

Supplementary Material

Click here to access/download Supplementary Material Supporting information.docx